Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 43, 3493-3496, August 1, 1983]
© 1983 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wilson, V. L.
Right arrow Articles by Momparler, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wilson, V. L.
Right arrow Articles by Momparler, R. L.

Inhibition of DNA Methylation in L1210 Leukemic Cells by 5-Aza-2'-deoxycytidine as a Possible Mechanism of Chemotherapeutic Action1

Vincent L. Wilson, Peter A. Jones and Richard L. Momparler2

Department of Biochemistry, School of Medicine, University of Southern California, Los Angeles [P. A. J.], and Division of Hematology-Oncology, Childrens Hospital of Los Angeles, Los Angeles, California 90027 [V. L. W., P. A. J.], and Département de Pharmacologie, Université de Montréal, and Centre de Recherche Pédiatrique, Hôpital Sainte-Justine, Montreal, Quebec, Canada H3T 1C5 [R. L. M.]

The relationship between antineoplastic activity of 5-aza-2'-deoxycytidine (5-aza-dCyd) in mice with L1210 leukemia and inhibition of DNA methylation was investigated. BALB/c x DBA/2 F1 mice with L1210 leukemia were given a 15-hr i.v. infusion of 5-aza-dCyd at a total dose ranging from 0.5 mg/kg (weak antineoplastic effect) to 22 mg/kg (very potent antineoplastic effect). The DNA of L1210 leukemia cells was isolated from 5-aza-dCyd-treated mice and tested for its ability to accept methyl groups from S-adenosyl-L-methionine in a reaction catalyzed by DNA methyltransferase. The methyl-accepting ability of leukemia cell DNA was found to be dependent on the dose of 5-aza-dCyd, suggesting that this therapy induced significant changes in the level of methylation of the DNA. At the start of the 5-aza-dCyd infusion, mice were given i.p. injections of [6-3H]uridine, and the DNA of the L1210 leukemia cells was isolated at the end of therapy. Analysis of the labeled pyrimidine bases showed that 5-aza-dCyd produced a dose-dependent reduction in the 5-methylcytosine content of the DNA. Thus, there appears to be a correlation between the antileukemic activity of 5-aza-dCyd and its ability to inhibit DNA methylation.

1 This investigation was supported by USPHS Grants GM 25739, Grant MA6356 from the Medical Research Council of Canada, and by LEUCAN.

2 To whom requests for reprints should be addressed, at Centre de Recherche Pédiatrique, Hopital Sainte-Justine, 3175 Chemin Sainte-Catherine, Montreal, Quebec, Canada H3T 1C5.

Received 8/16/82. Accepted 4/19/83.




This article has been cited by other articles:


Home page
The Annals of PharmacotherapyHome page
J. R Kuykendall
5-Azacytidine and Decitabine Monotherapies of Myelodysplastic Disorders
Ann. Pharmacother., October 1, 2005; 39(10): 1700 - 1708.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
P. M. Das and R. Singal
DNA Methylation and Cancer
J. Clin. Oncol., November 15, 2004; 22(22): 4632 - 4642.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
W.-G. Zhu, T. Hileman, Y. Ke, P. Wang, S. Lu, W. Duan, Z. Dai, T. Tong, M. A. Villalona-Calero, C. Plass, et al.
5-Aza-2'-deoxycytidine Activates the p53/p21Waf1/Cip1 Pathway to Inhibit Cell Proliferation
J. Biol. Chem., April 9, 2004; 279(15): 15161 - 15166.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
L. Shen, M. Toyota, Y. Kondo, T. Obata, S. Daniel, S. Pierce, K. Imai, H. M. Kantarjian, J.-P. J. Issa, and G. Garcia-Manero
Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia
Blood, May 15, 2003; 101(10): 4131 - 4136.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
J. Goffin and E. Eisenhauer
DNA methyltransferase inhibitors--state of the art
Ann. Onc., November 1, 2002; 13(11): 1699 - 1716.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Daskalakis, T. T. Nguyen, C. Nguyen, P. Guldberg, G. Kohler, P. Wijermans, P. A. Jones, and M. Lubbert
Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment
Blood, September 26, 2002; 100(8): 2957 - 2964.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
F Gounari, G R Banks, K Khazaie, P A Jeggo, and R Holliday
Gene reactivation: a tool for the isolation of mammalian DNA methylation mutants.
Genes & Dev., November 1, 1987; 1(9): 899 - 912.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1983 by the American Association for Cancer Research.